Forte Biosciences, Inc.
NASDAQ: FBRX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Paul A. Wagner
- Employees
- 14
- Headquarters
- Dallas, United States
- IPO year
- 2017
- Market cap
- $257.4M
- Website
- https://www.fortebiorx.com
Loading FBRX…
Loading profile data…Frequently asked questions about FBRX
What does Forte Biosciences, Inc. (FBRX) do?
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
Where does FBRX trade?
Forte Biosciences, Inc. (FBRX) trades on the NASDAQ Capital Market.
What sector is FBRX in?
Forte Biosciences, Inc. (FBRX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Forte Biosciences, Inc.?
Paul A. Wagner is the chief executive officer of Forte Biosciences, Inc. (FBRX).
Where is Forte Biosciences, Inc. headquartered?
Forte Biosciences, Inc. is headquartered in United States.
Does FBRX pay a dividend?
Forte Biosciences, Inc. (FBRX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FBRX go public?
Forte Biosciences, Inc. (FBRX) completed its initial public offering in 2017.